资产可视化：全球製药行业的卡车和追踪法规

本报告探讨资产可视化，重点关注全球製药行业的跟踪和追溯监管，并提供有关全球和区域监管环境、合规性、实施规模和范围、关键公司等方面的信息。

调查重点

• 关注新兴市场（巴西、南非、阿拉伯联合酋长国、沙特阿拉伯、土耳其）
• 识别区域和国家监管趋势之间的差异
• 各层级序列化对比分析

本报告回答的主要问题

• 连载规则介绍时间表
• 可追溯性的关键数据标准和义务是什么？
• 在国家法规中如何使用 GS1 等国际标准？

本报告所列公司

目录

• 执行摘要
• 全球监管环境
• 区域监管环境
• 主要用途
• 国内法规和国际标准
• 提案系统概述
• 合规：义务和自愿的最佳做法
• 报告要求
• 负责卡车和追踪的供应商/第三方
• 出色的分发工作
• 罚款和罚款
• 实施规模和范围
• 需要追踪的物品
• 建议的未来修復
• 结论
• 定义和缩写

Actionable Benefits:

• Strategic planning for pharmaceutical vendors and distributors for changes in serialization regulations.

• Gain insight into scale and scope of current regulations.

• Guidance into proposed future regulatory changes.

Research Highlights:

• Focus on emerging markets (Brazil, South Africa, UAE, Saudi Arabia, and Turkey)

• Identifies variation between region-level trends and country-level regulations.

• Comparison and analysis of different levels of serialization.

Critical Questions Answered:

• What is the timeline for implementation of serialization regulations?

• What are the key data standards and mandates for traceability?

• How are international standards like GS1 leveraged in national regulations?

Who Should Read This?

• Strategy planners and advisors within the pharmaceutical and supporting logistics industry.

• Managers aiming to identify regulatory requirements of their operations.

• For serialization software and hardware providers to assess regulatory impact on the pharmaceutical market.

Companies Mentioned:

Table of Contents

• Executive Summary
• Global Regulatory Environment
• Regional Regulatory Environment
• Key Objectives
• National Regulations and International Standards
• Summary of Proposed System
• Compliance: Mandates versus Voluntary Best Practices
• Reporting Requirements
• Suppliers and Third Parties Responsible for Track & Trace
• Good Distribution Practices
• Penalties and Fines
• Scale and Scope of Implementations
• Items Subject to Track & Trace
• Future Amendments Proposed
• Conclusion
• Definitions and Abbreviations